Papers
List our Papers
Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
Aurisicchio L, Salvatori E, Lione L, Bandini S, Pallocca M, Maggio R, Fanciulli M, De Nicola F, Goeman F, Ciliberto G, Conforti A, Luberto L, Palombo F.
J Exp Clin Cancer Res 2019, 14;38(1):78.
The perfect personalized cancer therapy: cancer vaccines against neoantigens.
Aurisicchio L, Pallocca M, Ciliberto G, Palombo F.
J Exp Clin Cancer Res. 2018 Apr 20;37(1):86. doi: 10.1186/s13046-018-0751-1
Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
Pala D, Rivara S, Mor M, Milazzo FM, Roscilli G, Pavoni E, Giannini G. Glycobiology. 2016 Jun;26(6):640-54. doi: 10.1093/glycob/cww003. Epub 2016 Jan 13.
Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.
Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS.
Oncogene. 2016 Mar 3;35(9):1206. doi: 10.1038/onc.2015.418. No abstract available.
Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G, De Vitis C, Ferrara FF, Noto A, Cherubini E, Ricci A, Mariotta S, Giarnieri E, Giovagnoli MR, Torrisi MR, Bergantino F, Costantini S, Fenizia F, Lambiase M, Aurisicchio L, Normanno N, Ciliberto G, Mancini R.
J Transl Med. 2016 Feb 29;14:61. doi: 10.1186/s12967-016-0816-x.